Abstract: The present invention relates to derivatives of aroyl-O-piperidine structure of the general formula (I): in which R1, R2, R3 and R4 are as defined in the description. Application of the compounds of the formula (I) to the treatment of hyper-triglyceridaemia, hypercholesterolaemia and dyslipidaemia, and to the prevention or treatment of obesity.

Abstract: The present invention relates to thiazolylpiperidine derivatives of the general formula (I): in which: A represents a radical chosen from the radicals a1 and a2 below: G represents a bond or a divalent radical chosen from the groups g1, g2 and g3 below: and R1, R2, R2?, R3, R4, R5, Y and Z are as defined in the description. Application of the compounds of the formula (I) to the treatment of hypertriglyceridaemia, hypercholesterolaemia and dyslipidaemia.

Abstract: The present invention relates to derivatives of aroyl-O-piperidine structure of the general formula (I): in which R1, R2, R3 and R4 are as defined in the description. Application of the compounds of the formula (I) to the treatment of hyper-triglyceridaemia, hypercholesterolaemia and dyslipidaemia, and to the prevention or treatment of obesity.

Abstract: The present invention relates to thiazolylpiperidine derivatives of the general formula (I): in which: A represents a radical chosen from the radicals a1 and a2 below: G represents a bond or a divalent radical chosen from the groups g1, g2 and g3 below: and R1, R2, R2?, R3, R4, R5, Y and Z are as defined in the description. Application of the compounds of the formula (I) to the treatment of hypertriglyceridaemia, hypercholesterolaemia and dyslipidaemia.

Abstract: The present invention relates to a compound of the formula (I): in which T, A, R, B Xi, Yi and n are as defined in Claim 1, and to the pharmaceutically usable derivatives, solvates and stereoisomers thereof, comprising a mixture thereof in all proportions, which can be used in the treatment of dyslipidaemia, and to pharmaceutical compositions comprising them.

Abstract: The present invention relates to compounds of the formula (I): in which: Z represents biphenyl optionally substitute in position 2′, 3′, 4′, 5′ and 6′ with one or more substitutents chosen from trihalomethyl and trihalomethoxy; Het represents quinolyl, quinoxalyl or pyridyl optionally substituted with one or more substitutents chosen from halo, cyano, nitro, (C1-C6)alkyl, (C6-C12)aryl, (C1-C6)alkoxy, hydroxyl, (C1-C6)thioalkoxy, carboxyl and (C1-C6)alkoxycarbonyl, or pharmaceutically acceptable salts thereof. These compounds are useful as inhibitors of microsomal triglyceride transfer protein and as inhibitors of the secretion of B apoproteins.

Abstract: The invention concerns novel compounds of general formula (1), their tautomeric forms, and their additive salts with pharmaceutically acceptable bases. The invention also concerns methods for preparing these compounds and their applications as medicines. These compounds inhibit the aldose reductase enzyme and can be used in the treatment or prevention of peripheral and autonomous neurological diabetic complications, renal and ocular disorders such as cataract and retinopathy.

Abstract: The present invention relates to the compounds of formula: 1

Abstract: The present invention relates to the compounds of formula: in which R1, R2, R3, E, A, X, Z, p and n are as defined herein. These compounds are aldose reductase inhibitors.

Abstract: The present invention relates to the compounds of formula: 1

Abstract: The invention concerns novel compound of general formula (1) in which: P, T1, T2, X and n are as defined in claim 1, their tautomeric forms, and their additive salts with pharmaceutically acceptable bases. The invention also concerns methods for preparing these compounds and their applications as medicines. These compounds inhibit the aldose reductase enzyme and can be used in the treatment or prevention of peripheral and autonomous neurological diabetic complications, renal and ocular disorders such as cataract and retinopathy.

Abstract: The present invention relates to the compounds of formula: ##STR1## in which R.sub.1, R.sub.2, R.sub.3, E, A, X, Z, p and n are as defined herein. These compounds are aldose reductase inhibitors.

Abstract: The present invention relates to the compounds of formula: ##STR1## in which R.sub.1, R.sub.2, R.sub.3, E, A, X, Z, p and n are as defined herein. These compounds are aldose reductase inhibitors.

Abstract: Novel 3,4-dihydro-4-oxo-3(prop-2-enyl)-1-phtalazineacetic acids and derivatives of formula (I) ##STR1## in which R.sub.1 R.sub.2 and R.sub.3 are the same or different and stand for H, a halogen or a linear or branched aliphatic, saturated or unsaturated radical, substituted or not by at least one halogen or R.sub.4 residue such as defined below, except when R.sub.4 is H; R.sub.4 and R.sub.5 are the same or different and stand for H, a linear or branched aliphatic radical, saturated or unsaturated, an aryl or heteroaryl radical, said radicals being substituted or not by at least one grouping such as fluorine, chlorine, bromine, methyl or trifluoromethyl, where R.sub.4 and R.sub.5 do not simultaneously denote H; R.sub.6 stands for hydroxy or alkoxy radical; R.sub.

Abstract: The present invention concerns new substituted sulfonamides, and the physiologically acceptable salts, complexes, esters and amides thereof, represented by the formula ##STR1## which is defined herein. Said compounds find application as anti-thrombotic and anti-asthmatic medicines.

Abstract: The present invention concerns new substituted sulfonamides, and the physiologically acceptable salts possibly in the form of complexes, esters and amides thereof, represented by the formula: ##STR1##

Abstract: Substituted six-membered benzo-fused heterocycles of the formula (I) ##STR1## in which: X=0, NH, S.fwdarw.(O).sub.n (n=0 or 2);R.sub.1 is phenyl, phenyl substituted by methoxy, hydroxy, chlorine, fluorine, diethylaminoethoxy, phenoxy, 2-methyl-4-thiazolyl, 2-amino-4-thiazolyl, phenyl, amino, nitro, terbutyl, carboxymethyl, acetamido, dimethyltriazenyl, benzoyl, hexyl, undecyl, trifluoromethyl, carbamoyl; or R.sub.1 is trifluoromethyl, pyridyl-2,pyridyl-4;R.sub.2 is H, methoxy, hydroxy; orR.sub.1 and R.sub.2 are --CH.dbd.CH--CH.dbd.CH--;R.sub.3 and R.sub.4 are methoxy, hydroxy, fluorine or form a fused benzene ring;CR.sub.5 R.sub.6 R.sub.7 is carboxymethyl, --CH.sub.2 --PO.sub.3 H,--CH.sub.2 --PO(oET).sub.2, 4-methylpiperazinyl, aminomethyl,3-4-5-trimethoxyphenylaminomethyl, acetyl, bromoacetyl, hydroxyethyl, acetoxyethyl, mercaptomethyl, acetylthiomethyl, methoxy-carbopnylthiomethyl, --CH--CONH.sub.2, ##STR2## substituted thiazolyl, subsituted furanone, imidazo(1,2-a)pyridinyl, indolizinyl, or R.sub.4 and R.

Abstract: The invention concerns [oxo-4-4H-[1]-benzopyran-8-yl]-alcanoic acids and their derivatives, their manufacture, represented by the formula. ##STR1## where AR is hydrogen, a phenyl radical which may or may not be substituted thenyl, furyl, naphthyl, a lower alkyl, cycloalkyl, aralkyl radical; B is a linear or branched lower alkyl radical, either saturated or ethylinically unsaturated; R.sub.1 is hydrogen or a phenyl radical; X is hydrogen or a lower alkyl or alkoxy radical and n=1, as well as salts, esters, aminoesters and amides.Compounds and their derivatives may be used as medicines, in particular in the control of tumors.

Abstract: The invention concerns: (oxo-4-4H-(1)-benzopyran-8-yl) alkanoic acids and their derivatives, their manufacture, represented by the formula: ##STR1## where Ar is hydrogen, a phenyl radical which may or may not be substituted, thenyl, furyl, naphthyl, a lower alkyl, cycloalkyl, aralkyl radical; B is a linear or branched lower alkyl radical, either saturated or ethylinically unsaturated; R.sub.1 is hydrogen or a phenyl radical; X is hydrogen or a lower alkyl or alkoxy radical and n=1, as well as salts, esters, aminoesters and amides.Compounds and their derivatives may be used as medicines, in particular in the control of tumors.

Abstract: The use of substituted flavonoid compounds which have the immunomodulatory activity of (1) boosting natural killer activity in vivo and (2) inducing interferon, and (3) belong to the family of flavonoids of the formula (I): ##STR1## in conjunction with interleukin-2 in cancer therapy is disclosed.